BioMarck Pharmaceuticals

About BioMarck Pharmaceuticals

BioMarck Pharmaceuticals, Ltd. operates as a biopharmaceutical company focused on developing drugs for severe respiratory diseases and various forms of cancer. Founded in 2001 by Kenneth Adler and Indu Parikh, the company's scientific foundation is built upon the discoveries of Dr. Adler, a professor of cell biology at North Carolina State University, who has dedicated over three decades to researching airway diseases. The company's technology was licensed on a worldwide exclusive basis from the university. Dr. Parikh brought extensive experience in drug discovery and development from previous roles at RTP Pharma, Glaxo Inc., and Burroughs Wellcome Co.

The company's core technology revolves around inhibiting the MARCKS (myristoylated alanine-rich C Kinase Substrate) protein, which is a key molecule in processes like mucus secretion, inflammation, and cell movement. BioMarck's business model is centered on the clinical development and subsequent commercialization of its portfolio of patented compounds that target the MARCKS protein. The primary source of funding has been through multiple financing rounds, including Series C funding, and grants from institutions like the National Institutes of Health (NIH). The company has raised approximately $22 million over 11 rounds to support its research and clinical trials.

BioMarck's lead product candidate is BIO-11006, a synthetic peptide delivered as an inhaled aerosol. This compound is designed to offer a dual-function therapy by inhibiting both mucus secretion and inflammation. The primary therapeutic areas targeted by BIO-11006 include Chronic Obstructive Pulmonary Disease (COPD), particularly chronic bronchitis, Acute Respiratory Distress Syndrome (ARDS), and non-small cell lung cancer (NSCLC). Clinical trials have been a significant part of BioMarck's journey. The company has advanced BIO-11006 through Phase 1 and Phase 2 studies to evaluate its safety and efficacy. A Phase 2a study in patients with moderate to severe ARDS showed a reduction in all-cause mortality. Another Phase 2 trial was launched to study BIO-11006 in combination with standard chemotherapy for advanced NSCLC. The company has also received FDA allowance to begin human trials for BIO-11006 as a treatment for adults with lung cancer and has been involved in providing the drug for compassionate use in children with specific cancers.